Advances in Cellular Therapy

Currently, no curative therapies are available for many malignant diseases and autoimmune disorders. Over the past two decades, however, substantial progress has been made in our understanding of immunity and immune tolerance. Numerous immune mechanisms were found to be responsible for breaking the state of tolerance and for inducing specific cytotoxic immunity. In parallel, much knowledge has been gained on how immune tolerance can be reinduced in autoimmune diseases. The authors of the this Special Issue would like to add value to the current advances in cellular therapy for treating cancer as well as for inducing immune tolerance in autoimmune diseases. In addition, new insights into stem cell research and transplantation in autoimmune diseases are presented and future perspectives are given.

References

• 1 Steinman RM. The dendritic cell system and its role in immunogenicity.  Annu Rev Immunol. 1991;  9 271-296
• 2 Banchereau J, Briere F, Caux C. et al . Immunobiology of dendritic cells.  Annu Rev Immunol. 2000;  18 767-811
• 3 Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6.  Immunity. 2003;  19 225-234
• 4 Fernandez NC, Lozier A, Flament C. et al . Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo.  Nat Med. 1999;  5 405-411
• 5 Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity.  J Exp Med. 2002;  195 9-14
• 6 Kadowaki N, Antonenko S, Ho S. et al . Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells.  J Exp Med. 2001;  193 1221-1226
• 7 Taieb J, Chaput N, Menard C. et al . A novel dendritic cell subset involved in tumor immunosurveillance.  Nat Med. 2006;  12 214-219
• 8 Chan CW, Crafton E, Fan HN. et al . Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity.  Nat Med. 2006;  12 207-213
• 9 Ullrich E, Bonmort M, Mignot G. et al . Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells.  Cancer Res. 2007;  67 851-853
• 10 Sbiera S, Wortmann S, Fassnacht M. Dendritic cell based immunotherapy - a promising therapeutic approach for endocrine malignancies.  Horm Metab Res. 2008;  40 89-98
• 11 Ullrich E, Chaput N, Zitvogel L. Killer dendritic cells and their potential role in immunotherapy.  Horm Metab Res. 2008;  40 75-81
• 12 Papewalis C, Jacobs B, Wuttke M. et al . IFN-alpha skews monocytes into CD56+ expressing dendritic cells with potent functional activities in vitro and in vivo.  J Immunol. 2008;  180 1462-1470
• 13 Jacobs B, Wuttke M, Papewalis C. et al . Characterization of monocyte-derived IFN-generated dendritic cells.  Horm Metab Res. 2008;  40 117-121
• 14 Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease.  Nat Rev Immunol. 2007;  7 665-677
• 15 Jaeckel E, Mpofu N, Saal N, Manns MP. Role of regulatory T cells for the treatment of type 1 diabetes mellitus.  Horm Metab Res. 2008;  40 126-136
• 16 Seissler J, Schott M. Generation of insulin-producing beta cells from stem cells - perspectives for cell therapy in type 1 diabetes.  Horm Metab Res. 2008;  40 155-161
• 17 Lee DD, Grossman E, Chong AS. Cellular Therapies for Type 1 Diabetes.  Horm Metab Res. 2008;  40 147-154

Correspondence